Clinical Trial Update: SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating SU5416 in combination with doxorubicin in stage IIIB or stage IV inflammatory breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Breast Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• SU5416 (semaxanib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED